Matthew Reaney

3.0k total citations · 2 hit papers
106 papers, 2.0k citations indexed

About

Matthew Reaney is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and General Health Professions. According to data from OpenAlex, Matthew Reaney has authored 106 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Endocrinology, Diabetes and Metabolism, 21 papers in Economics and Econometrics and 11 papers in General Health Professions. Recurrent topics in Matthew Reaney's work include Diabetes Management and Research (33 papers), Diabetes Treatment and Management (27 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). Matthew Reaney is often cited by papers focused on Diabetes Management and Research (33 papers), Diabetes Treatment and Management (27 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). Matthew Reaney collaborates with scholars based in United Kingdom, United States and France. Matthew Reaney's co-authors include Jane Speight, Lauren Nelson, Magaly Perez‐Nieves, Amy J. Sehnert, Laurent Eckert, Simon Cleall, Kristina S. Boye, John A. Spertus, Sarah Clifford and Sara Saberi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Matthew Reaney

102 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

2019 231 citations Matthew Reaney, Vera Mastey et al. profile →
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2021 127 citations John A. Spertus, Jennifer Fine et al. profile →

Peers

Countries citing papers authored by Matthew Reaney

Since Specialization

Citations

This map shows the geographic impact of Matthew Reaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Reaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Reaney more than expected).

Fields of papers citing papers by Matthew Reaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Reaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Reaney. The network helps show where Matthew Reaney may publish in the future.

Co-authorship network of co-authors of Matthew Reaney

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Reaney. A scholar is included among the top collaborators of Matthew Reaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Reaney. Matthew Reaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Consistent Lack of Consistency: Definitions, Evidentiary Expectations and Potential Use of Meaningful Change Data in Clinical Outcome Assessments Across Stakeholders. Results from a DIA Working Group Literature Review and Survey 2025 ·Therapeutic Innovation & Regulatory Science ·Matthew Reaney, Vivian H. Shih, Alison Wilson, Bill Byrom, Nenad Medić, Dorothee Oberdhan, Carla Mamolo, Mrinmoy Majumder	2
2	Life After Invasive Meningococcal Disease: Insights from Survivors and Their Caregivers 2024 ·Infectious Diseases and Therapy ·(unknown), (unknown), (unknown), Matthew Reaney, (unknown), (unknown), (unknown), (unknown), (unknown), Sofia B. Pinto, (unknown), (unknown)	2
3	Initial Experiences with Invasive Meningococcal Disease: Insights from Survivors and Their Caregivers 2024 ·Infectious Diseases and Therapy ·(unknown), (unknown), (unknown), Matthew Reaney, (unknown), (unknown), (unknown), (unknown), (unknown), Sofia B. Pinto, (unknown), (unknown)	2
4	The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class 2024 ·Journal of Cardiac Failure ·(unknown), John A. Spertus, Kensey Gosch, Andrew Z. Wang, Perry Elliott, Neal K. Lakdawala, Matthew Reaney, (unknown), Jenny Lam, Kathleen W. Wyrwich, Andrew J. Sauer	5
5	Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial 2024 ·Future Oncology ·Alexander J. Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D. Lewis, Ketty Peris, Oliver Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, (unknown), (unknown), (unknown), Suk-Young Yoo, Kosalai Kal Mohan, (unknown), Timothy G. Bowler, Matthew G. Fury, Aleksander Sekulic	0
6	Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial 2022 ·PharmacoEconomics - Open ·Matthew Reaney, (unknown), (unknown), John A. Spertus, Chantal Dolan, Amy J. Sehnert, Jennifer Fine	2
7	Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument 2022 ·PharmacoEconomics - Open ·Matthew Reaney, (unknown), Amy J. Sehnert, (unknown), Albert Hagège, Srihari S. Naidu, Iacopo Olivotto	8
8	Development of an Item Bank to Assess Patient-Reported Outcomes: Signs, Symptoms, and Impacts of COVID-19 2022 ·Patient ·Matthew Reaney, James Turnbull, Jean Paty, (unknown), Chad Gwaltney	1
9	Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures 2022 ·ERJ Open Research ·Marlies Wijsenbeek, María Molina‐Molina, Olivier Chassany, John P. Fox, Liam Galvin, Klaus Geißler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O’Brien, Ashley F. Slagle, (unknown), Matthew Reaney, Michael Baldwin, (unknown), Klaus Röhr, Jeff Swigris, Κατερίνα Αντωνίου	10
10	Encouraging foot care in people with and without diabetes through narrative communication 2021 ·Journal of Health Psychology ·Matthew Reaney, Thomas E. Gladwin, Nik Chmiel, Susan Churchill	5
11	Information about foot care provided to people with diabetes with or without their partners: Impact on recommended foot care behavior 2021 ·Applied Psychology Health and Well-Being ·Matthew Reaney, Thomas E. Gladwin, Susan Churchill	4
12	783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 2021 ·Annals of Oncology ·Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andréia Cristina de Melo, (unknown), Alla Lisyanskaya, Vanessa Samouëlian, (unknown), (unknown), Fernanda Damian, Chang Cl, Shunji Takahashi, (unknown), Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, James Harnett, Chun‐I Chen, Krishnansu S. Tewari	2
13	Generating Relevant Information from Patients in the Technology-Enhanced Era of Patient-Focused Drug Development: Opportunities and Challenges 2020 ·Patient ·Matthew Reaney, (unknown), (unknown), (unknown)	3
14	Patient Experience Information: Streamlining and Harmonizing the Collection of Patient Preference and Patient-Reported Outcomes Data 2020 ·Pharmaceutical Medicine ·Matthew Reaney, Ana María Rodríguez	0
15	Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone 2020 ·Diabetes Technology & Therapeutics ·Thomas Danne, Vijay N. Joish, (unknown), Phillip Banks, Sangeeta Sawhney, Pablo Lapuerta, Michael J. Davies, John B. Buse, Dee Lin, Matthew Reaney, (unknown), Frank J. Snoek, Timothy S. Bailey, William H. Polonsky	7
16	“Lower abdominal pains, as if I was being squeezed…in a clamp”: A Qualitative Analysis of Symptoms, Patient-Perceived Side Effects and Impacts of Ovarian Cancer 2019 ·Patient ·Mona L. Martin, Katarina Halling, Daniel Eek, Matthew Reaney	6
17	The Potential Role of Individual-Level Benefit-Risk Assessment in Treatment Decision Making: A DIA Study Endpoints Community Workstream 2018 ·Therapeutic Innovation & Regulatory Science ·Matthew Reaney, Elizabeth Nicole Bush, (unknown), Jean Paty, Aude Roborel de Climens, Søren Skovlund, Linda Nelsen, Emuella Flood, Adam Gater	12
18	The QoL-Q diabetes' : a novel instrument to assess quality of life for adults with Type 1 diabetes undergoing complex interventions including transplantation 2010 ·Diabetic Medicine ·Jane Speight, Andrée Woodcock, Matthew Reaney, Stephanie A. Amiel, Paul Johnson, N. Parrott, Martin K. Rutter, Peter Senior, Rachel Vickers‐Smith, (unknown)	6
19	Expectations and experiences of transplant : a qualitative study of people with Type 1 diabetes undergoing pancreatic islet transplantation 2009 ·Diabetic Medicine ·Jane Speight, Andrée Woodcock, Matthew Reaney, Stephanie A. Amiel, (unknown), N. Parrott, Peter Senior, Jane Shaw	3
20	Not all roads lead to Rome—a review of quality of life measurement in adults with diabetes 2009 ·Diabetic Medicine ·Jane Speight, Matthew Reaney, (unknown)	203

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact